Clinical Trial Update: An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection [Phase 2]

View source ↗

Summary

This Phase 2 open-label study evaluated DAS181 delivered by dry powder inhaler or nebulized formulation in immunocompromised patients with parainfluenza infecti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parainfluenza Virus Infection

Drugs mentioned

• DAS181

Snippet

Sponsor: Ansun Biopharma, Inc. | Conditions: Parainfluenza | Phase 2 | Status: COMPLETED